Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

INBX
Inhibrx Biosciences, Inc. Common Stock
stock NASDAQ

Market Open
Aug 11, 2026 2:21:43 PM EDT
92.47USD-0.858%(-0.80)84,628
92.05Bid   93.00Ask   0.95Spread
Pre-market
Aug 11, 2026 9:11:30 AM EDT
93.50USD+0.247%(+0.23)222
After-hours
Aug 7, 2026 4:10:30 PM EDT
88.00USD-0.806%(-0.71)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
10:05AM EST  Mid-Morning Market Update: Markets Open Lower; Johnson & Johnson Sales Miss Views   Benzinga
Jan 5, 2022
07:46AM EST  Inhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors   Benzinga
Jan 4, 2022
04:06PM EST  Inhibrx Announces Initial Phase 1 Dose Escalation Results For INBRX-106 In Combination With Keytruda Along With Updated Single Agent Data   Benzinga
04:05PM EST  Novel Hexavalent OX40 Agonist, in Combination with Keytruda(r) (Pembrolizumab) Along with Updated Single Agent Data   PR Newswire
Dec 2, 2021
06:59AM EST  Inhibrx Precision Cancer Antibody Receives FDA Orphan Drug Tag For Rare Bone Cancer   Benzinga
Dec 1, 2021
04:12PM EST  Inhibrx Receives FDA Orphan-Drug Designation For INBRX-109 In Chondrosarcoma   Benzinga
Nov 10, 2021
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
07:33AM EST  Credit Suisse Maintains Outperform on Inhibrx, Raises Price Target to $53   Benzinga
Nov 9, 2021
05:35PM EST  Inhibrx Q3 EPS $(0.54) Up From $(0.77) YoY   Benzinga
04:06PM EST  Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate   PR Newswire
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
Nov 3, 2021
08:02AM EDT  Inhibrx Announces Presentations at SITC 2021   PR Newswire
Nov 2, 2021
10:53AM EDT  JMP Securities Maintains Market Outperform on Inhibrx, Raises Price Target to $53   Benzinga
Nov 1, 2021
05:52PM EDT  Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences   PR Newswire
Oct 28, 2021
08:31AM EDT  Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors   PR Newswire
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
07:38AM EDT  Inhibrx : Phase 1 Trial Of INBRX-101 Shows Potential To Achieve Normal Alpha-1 Antitrypsin Levels With Monthly Dosing   RTTNews
07:31AM EDT  Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing   PR Newswire
Oct 11, 2021
04:08PM EDT  Inhibrx To Host Webcast Presentation Of Interim Results From The Phase 1 Trial Of INBRX-101, Its Recombinant Human AAT-Fc Protein For The Treatment Of Alpha-1 Antitrypsin Deficiency   Benzinga
04:05PM EDT  of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency   PR Newswire
Sep 21, 2021
10:33AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2021   Benzinga
07:13AM EDT  JMP Securities Initiates Coverage On Inhibrx with Market Outperform Rating, Announces Price Target of $46   Benzinga
Sep 13, 2021
04:30PM EDT  Inhibrx Announces Participation in Upcoming Investor Conference   PR Newswire
Aug 9, 2021
05:24PM EDT  Inhibrx Q2 EPS $(0.55) Up From $(0.99) YoY   Benzinga
04:39PM EDT  Inhibrx Reports Second Quarter 2021 Financial Results   PR Newswire
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
06:50AM EDT  Inhibrx Launches Mid-Stage Bone Cancer Study With INBRX-109, Amends Loan Agreement With Oxford   Benzinga
Jun 21, 2021
04:08PM EDT  Inhibrx Says Initiates Potential Registration-Enabling Phase 2 Study Of INBRX-109 In Conventional Chondrosarcoma Patients; Says Updates Data For Ongoing Phase 1 Study; Announces Amended Loan Agreement With Oxford   Benzinga
04:05PM EDT  in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford   PR Newswire
May 17, 2021
04:05PM EDT  Inhibrx Announces Participation in Upcoming Investor Conferences   PR Newswire
May 13, 2021
04:53PM EDT  Inhibrx Q1 EPS $(0.51) Up From $(1.11) YoY   Benzinga
04:10PM EDT  Inhibrx Reports First Quarter 2021 Financial Results   PR Newswire
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
Mar 12, 2021
11:53AM EST  Inhibrx's INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study   Benzinga
09:03AM EST  Inhibrx Announces Phase 1 Single Agent Dose Escalation Results For INBRX-105, A Novel Targeted 4-1BB Agonist   Benzinga
09:01AM EST  Inhibrx Q4 EPS $(0.47)   Benzinga
09:01AM EST  Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist   PR Newswire
Feb 1, 2021
05:43PM EST  Inhibrx Announces Participation in Upcoming Investor Conference   PR Newswire
Jan 13, 2021
09:04AM EST  Inhibrx Granted Fast Track Designation For INBRX-109 For The Treatment Of Unresectable Or Metastatic Conventional Chondrosarcoma Patients   Benzinga
09:02AM EST  Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of   PR Newswire
Jan 5, 2021
09:08AM EST  Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106   Benzinga
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 17, 2020
08:10AM EST  The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut   Benzinga
Dec 16, 2020
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 4, 2020
08:04AM EST  The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs   Benzinga
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 13, 2020
04:18PM EST  Inhibrx Q3 EPS $(0.77) Misses $(0.60) Estimate, Sales $5.90M Beat $1.00M Estimate   Benzinga
04:10PM EST  Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces   PR Newswire
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
Nov 11, 2020
04:15PM EST  Inhibrx Announces Interim Results From Phase 1 Trial Of INBRX-109; Says Disease Control Observed In 92% Of Patients   Benzinga
04:12PM EST  Inhibrx Announces Positive Interim Results From Phase 1 Trial Of INBRX-109 Chondrosarcoma Patients   Benzinga
04:12PM EST  Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109   PR Newswire
Nov 5, 2020
04:05PM EST  Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences   PR Newswire
Nov 3, 2020
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
Sep 14, 2020
10:25AM EDT  Why Inhibrx's Stock Is Trading Higher Today   Benzinga
08:49AM EDT  Jefferies Initiates Coverage On Inhibrx with Buy Rating, Announces Price Target of $30   Benzinga
05:10AM EDT  Evercore ISI Group Initiates Coverage On Inhibrx with Outperform Rating, Announces Price Target of $30   Benzinga
05:09AM EDT  Credit Suisse Initiates Coverage On Inhibrx with Outperform Rating, Announces Price Target of $26   Benzinga
Aug 29, 2020
03:34PM EDT  Notable Insider Buys Last Week: Avis Budget, Axis Capital And More   Benzinga
Aug 25, 2020
12:17PM EDT  Oxford Finance Announces $10 Million Credit Facility with Inhibrx, Inc.   PR Newswire
Aug 21, 2020
04:00PM EDT  Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full   PR Newswire
Aug 19, 2020
10:09AM EDT  Inhibrx Shares Indicating At $34 On 128K Shares   Benzinga
06:21AM EDT  Inhibrx Priced 7M Share IPO @$17/Share   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC